Thorium-228 is the parent radionuclide of Lead-212 (Pb-212), an isotope increasingly used in the development of targeted radiotherapeutics. Using a proprietary Th-228/Pb-212 generator platform, Pb-212 can be reliably supplied for research and clinical use. The technology underpins several ongoing clinical trials evaluating innovative cancer treatment approaches.